ITIC vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ITIC presents a contradictory profile characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health, despite an exceptionally clean balance sheet with a Debt/Equity ratio of 0.03. While the stock trades below its Graham Number ($243.61), suggesting defensive value, it sits significantly above its growth-based intrinsic value ($129.92) amid negative YoY revenue (-1.60%) and earnings growth (-10.10%). The technical trend is purely bearish (0/100), and the lack of analyst coverage suggests a neglected small-cap position. Overall, the company is financially stable but operationally stagnant.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
ITIC vs JPM: Head-to-Head Comparison
This page compares Investors Title Company (ITIC) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.